The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse - PubMed (original) (raw)
The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse
D C German et al. Neurodegeneration. 1996 Dec.
Abstract
The neurotoxin MPTP has been used to create an animal model of Parkinson's disease in the mouse, in part, because it causes a significant loss of dopaminergic neurons in the substantia nigra (nucleus A9). The purpose of the present study was to determine whether MPTP also causes degeneration of midbrain dopaminergic neurons in nuclei A8 and A10 in the mouse, as occurs in humans with Parkinson's disease. Two commonly used strains of mice were used: FVB/N and C57BL/6. MPTP was administered in cumulative doses of 50-300 mg/kg. Seven days later, dopamine concentrations were measured in the striatum using high performance liquid chromatography, and midbrain dopaminergic neurons were identified using an antibody against tyrosine hydroxylase. The cell locations were mapped with a computer imaging system. In the FVB/N strain, there was a dose-dependent decrease in striatal dopamine concentrations. Although the highest dose (300 mg/kg) caused an 86% reduction in striatal dopamine concentrations, there was only a moderate and non-significant loss of midbrain dopaminergic neurons. In the C57BL/6 strain, however, a high dose of MPTP (240 mg/kg) caused a significant reduction in both striatal dopamine concentrations (95%), and midbrain dopaminergic cells; 69% loss of nucleus A8 cells, 75% loss of nucleus A9 cells, and in nucleus A10 subnuclei there was 42% loss of ventral tegmental area cells, 55% loss of interfascicular nucleus cells, and no loss of cells in the central linear nucleus. These data (1) provide further evidence for differential susceptibility to MPTP toxicity among different mouse strains, (2) indicate that a significant depletion of striatal dopamine is not necessarily due to degeneration of midbrain dopaminergic neurons, (3) provide the precise locations of midbrain dopaminergic cells that are vulnerable to MPTP, which will aid future studies that seek to determine the mechanism/s by which-MPTP selectively destroys only certain midbrain dopaminergic neurons, and (4) indicate that MPTP produces midbrain dopaminergic neuronal degeneration in the same nuclei in the C57BL16 mouse that degenerate in humans with Parkinson's disease.
Similar articles
- Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration.
Liang CL, Sinton CM, Sonsalla PK, German DC. Liang CL, et al. Neurodegeneration. 1996 Dec;5(4):313-8. doi: 10.1006/neur.1996.0042. Neurodegeneration. 1996. PMID: 9117542 - Midbrain dopaminergic neurons in the mouse: co-localization with Calbindin-D28K and calretinin.
Liang CL, Sinton CM, German DC. Liang CL, et al. Neuroscience. 1996 Nov;75(2):523-33. doi: 10.1016/0306-4522(96)00228-x. Neuroscience. 1996. PMID: 8931015 - 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost?
German DC, Dubach M, Askari S, Speciale SG, Bowden DM. German DC, et al. Neuroscience. 1988 Jan;24(1):161-74. doi: 10.1016/0306-4522(88)90320-x. Neuroscience. 1988. PMID: 3259295 - The role of otx2 in adult mesencephalic-diencephalic dopaminergic neurons.
Simeone A, Di Salvio M, Di Giovannantonio LG, Acampora D, Omodei D, Tomasetti C. Simeone A, et al. Mol Neurobiol. 2011 Apr;43(2):107-13. doi: 10.1007/s12035-010-8148-y. Epub 2010 Nov 18. Mol Neurobiol. 2011. PMID: 21086067 Review. - Foxa1 and Foxa2 transcription factors regulate differentiation of midbrain dopaminergic neurons.
Ang SL. Ang SL. Adv Exp Med Biol. 2009;651:58-65. doi: 10.1007/978-1-4419-0322-8_5. Adv Exp Med Biol. 2009. PMID: 19731550 Review.
Cited by
- Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update.
Brichta L, Greengard P. Brichta L, et al. Front Neuroanat. 2014 Dec 15;8:152. doi: 10.3389/fnana.2014.00152. eCollection 2014. Front Neuroanat. 2014. PMID: 25565977 Free PMC article. Review. - Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE. Bezard E, et al. J Neurosci. 2001 Sep 1;21(17):6853-61. doi: 10.1523/JNEUROSCI.21-17-06853.2001. J Neurosci. 2001. PMID: 11517273 Free PMC article. - Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism.
Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM, Smulson ME, Hoffman BE, Guastella DB, Dawson VL, Dawson TM. Mandir AS, et al. Proc Natl Acad Sci U S A. 1999 May 11;96(10):5774-9. doi: 10.1073/pnas.96.10.5774. Proc Natl Acad Sci U S A. 1999. PMID: 10318960 Free PMC article. - Antioxidant Formulae, Shengmai San, and LingGuiZhuGanTang, Prevent MPTP Induced Brain Dysfunction and Oxidative Damage in Mice.
Giridharan VV, Thandavarayan RA, Konishi T. Giridharan VV, et al. Evid Based Complement Alternat Med. 2015;2015:584018. doi: 10.1155/2015/584018. Epub 2015 Nov 5. Evid Based Complement Alternat Med. 2015. PMID: 26612995 Free PMC article. - Genetic variability of respiratory complex abundance, organization and activity in mouse brain.
Buck KJ, Walter NA, Denmark DL. Buck KJ, et al. Genes Brain Behav. 2014 Feb;13(2):135-43. doi: 10.1111/gbb.12101. Epub 2013 Nov 15. Genes Brain Behav. 2014. PMID: 24164700 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases